Melphalan Sun (Melphalan)

Melphalan forms covalent bonds with the N7 position of guanine in DNA, creating cross‑links that block DNA replication and transcription. This damage triggers cell‑cycle arrest and apoptosis, preferentially affecting rapidly dividing cancer cells while sparing most normal tissues.

The dose of Melphalan Sun is individualized by the prescribing oncologist based on the specific cancer type, treatment protocol, patient weight, renal function, and prior therapy. Only a qualified healthcare professional can determine the appropriate dosing schedule.

Melphalan is classified as potentially teratogenic and is contraindicated during pregnancy. It can also be excreted in breast milk, posing a risk to the infant. Women of child‑bearing potential should use effective contraception and discuss risks with their physician before treatment.

To request Melphalan Sun, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Melphalan shares the DNA‑cross‑linking mechanism of other alkylators such as cyclophosphamide, but it is often preferred for certain haematologic malignancies like multiple myeloma due to its potency and pharmacokinetic profile. Choice of agent depends on tumour type, prior therapy, and individual patient tolerance.

Melphalan Sun should be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

Melphalan Sun is given by intravenous infusion under the supervision of qualified medical personnel. The infusion rate and duration are determined by the treatment protocol and patient tolerance, and the drug is typically administered in a clinical setting such as an oncology centre.

The most serious risks include severe bone‑marrow suppression leading to infection or bleeding, secondary malignancies, pulmonary toxicity, and renal impairment. Patients should be closely monitored for signs of infection, respiratory distress, and changes in kidney function throughout therapy.

Melphalan Sun is contraindicated in patients with known hypersensitivity to melphalan or related alkylating agents, those who are pregnant or breastfeeding, and individuals with severe pre‑existing bone‑marrow failure, uncontrolled infections, or significant renal or hepatic impairment unless benefits outweigh risks.